Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupHKSE:02096 -2.45%94 EBITDA Margin % is 21.68% as of Dec. 2025, which is 11% below its 10-year median of 24.29. GuruFocus rates HKSE:02096 with a GF Score™ of 94/100 and a GF Value™ of HK$10.74 (Modestly Overvalued). Among 959 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 69.86% on this metric.
Simcere Pharmaceutical Group (HKSE:02096) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Simcere Pharmaceutical Group EBITDA Margin % Related Terms
Simcere Pharmaceutical Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group EBITDA Margin % Chart
HKSE:02096 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (HKSE:02096) has a EBITDA Margin % of 21.68% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Simcere Pharmaceutical Group and its competitors. This is 11% below median its historical median of 24.29. Over the past decade, Simcere Pharmaceutical Group's EBITDA Margin % has ranged from 16.41 to 34.49. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #289 out of 959 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Simcere Pharmaceutical Group's EBITDA Margin % too high?
Simcere Pharmaceutical Group's current EBITDA Margin % of 21.68% is 11% below median its 10-year median of 24.29. Over the past 10 years, this metric has ranged from a low of 16.41 to a high of 34.49. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Simcere Pharmaceutical Group's value of 21.68% is 73.6% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #289 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #289 out of 959 companies for EBITDA Margin %. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Simcere Pharmaceutical Group's value of 21.68% is 73.6% above this benchmark. Historically, Simcere Pharmaceutical Group's own EBITDA Margin % has ranged from 16.41 to 34.49 over the past decade. While the company's 10-year median is 24.29 vs. the industry median of 12.49, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current EBITDA Margin % of 21.68% is 73.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EBITDA Margin % is 21.68%, which is 11% below median its own 10-year median of 24.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (HKSE:02096) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$10.74, compared to a current price of HK$12.73 — trading 18.5% above its estimated fair value. The current EBITDA Margin % is 21.68%, which is 11% below median its 10-year median of 24.29 and 73.6% above the Drug Manufacturers industry median of 12.49. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Simcere Pharmaceutical Group (HKSE:02096), the current EBITDA Margin % is 21.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (HKSE:02096) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of HK$12.73 is trading 18.5% above its estimated GF Value™ of HK$10.74.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for HKSE:02096:
EBITDA Margin %: 21.68% (11% below median its 10-year median of 24.29)
GF Value™: HK$10.74 vs. price of HK$12.73 (18.5% above fair value)
Industry Position: 73.6% above the Drug Manufacturers median (#289 of 959)
No single metric tells the full story. See the HKSE:02096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for HKSE:02096
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02096 has been successfully added to your 
